Physician profile
Bradley Mcelroy
NPI 1043248636
$58,184.47
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $407 · 2021: $6,355 · 2022: $18K · 2023: $1,379 · 2024: $15.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Food and Beverage | $394.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $54,889.78 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $1,452.20 | 2019-2023 | Watchman Access System |
| Medtronic, INC. | $336.85 | 2021-2023 | Azure Xt Dr Mri Surescan |
| Novartis Pharmaceuticals Corporation | $294.21 | 2019-2020 | |
| Amgen INC. | $263.45 | 2019-2022 | |
| Abiomed | $234.10 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.85 | 2019-2023 | Lifevest |
| Abbott Laboratories | $100.85 | 2019-2023 | Cardiomems |
| Sanofi-Aventis U.S. LLC | $87.57 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $79.11 | 2019-2023 | Eliquis |
| Actelion Pharmaceuticals US, INC. | $53.22 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $46.04 | 2022-2024 | Verquvo, Lagevrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.33 | 2019-2023 | Jardiance |
| Portola Pharmaceuticals, LLC | $30.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $25.95 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elutia, INC. | $25.49 | 2019 | |
| Pfizer INC. | $24.06 | 2019-2020 | |
| Chiesi USA, INC. | $17.62 | 2023 | Cleviprex, Kengreal |
| Philips North America LLC | $15.47 | 2023 | |
| Penumbra, INC. | $15.47 | 2022 | |
| Progenics Pharmaceuticals, INC. | $14.33 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.97 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Mcelroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.